Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Human stem cell-derived hepatic cells recapitulate polygenic risk in MASLD development and highlight CD36 as a key mediator.

Life sciences - 1 Oct 2026

Gatzios Alexandra, Stinckens Marth, Verhoeven Anouk, Rombaut Matthias, De Win Dinja, Heymans Anja, Loosen Arne, Van Goethem Freddy, De Kock Joery, Rodrigues Robim M, Boeckmans Joost, Vanhaecke Tamara

Abstract excerpt

Several genetic variants have been identified that impact outcomes in patients with metabolic dysfunction-associated steatohepatitis (MASH), but cellular platforms to identify molecular targets for treatment remain scarce. This study aims to employ a polygenic risk score for hepatic fat content (PRS-HFC) in a human-based in vitro model to identify potential druggable targets related to a genetic risk for MASH....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CD36 Antigens
Share to Fatty Liver

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Risk Score

Share to Hepatocytes

Share to Lipid Metabolism

Share to Multifactorial Inheritance

Share to Oxidative Stress

Share to Stem Cells

Source

Identifiers

PMID: 42442603
DOI: 10.1016/j.lfs.2026.124587

Genes

CD36

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Human stem cell-derived hepatic cells recapitulate polygenic risk in MASLD development and highlight CD36 as a key mediator.PMID 42442603Read ↗

Modeling Familial MASH by iPSC-HepatocytesSemantic proximity Read ↗

Predicting Metabolic Dysfunction Associated Steatotic Liver Disease Risk Using Patient-Derived Induced Pluripotent Stem CellsSemantic proximity Read ↗

Genomic Signatures of MASLD: How Genomics Is Redefining Our Understanding of Metabolic Liver DiseaseSemantic proximity Read ↗

Leveraging Human Genetics to Identify Potential New Treatments for Fatty Liver Disease.Semantic proximity Read ↗

Profiling the genome and proteome of metabolic dysfunction-associated steatotic liver disease identifies potential therapeutic targetsSemantic proximity Read ↗

Polygenic risk score of metabolic dysfunction-associated steatotic liver disease amplifies the health impact on severe liver disease and metabolism-related outcomes.Semantic proximity Read ↗

Cross-trait genomic modeling reveals the polygenic architecture and systemic impact of MASLD.Semantic proximity Read ↗

Monogenic and Polygenic Risk in Common Liver Diseases: Implications for Clinical Care.Semantic proximity Read ↗

MetALD: Genetic Factors and Clinical Outcomes.Semantic proximity Read ↗

Mapping the genomic landscape of MASLD: A framework for molecular subtyping and precision hepatology.Semantic proximity Read ↗

Human Induced Pluripotent Stem Cell based Hepatic-Modeling of Lipid metabolism associated TM6SF2 E167K variantSemantic proximity Read ↗

Characterization Of Human Pluripotent Stem Cell-Derived Hepatocytes With Adult Features And Potential For Modeling Metabolic DiseasesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.